CAU
NUVB icon

Caxton Associates (UK)’s Nuvation Bio NUVB Stock Holding History

Caxton Associates (UK)’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-47,827
Closed -$205K – 906
2026
Q1 		$205K Sell
47,827
-537,108
-92% -$2.99M ﹤0.01% 718
2025
Q4 		$5.24M Buy
584,935
+392,650
+204% +$2.43M 0.1% 62
2025
Q3 		$711K Buy
+192,285
New +$524K 0.02% 399

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Caxton Associates (UK)'s NUVB Position: Q2 2026 in Review

Caxton Associates (UK) sold out of Nuvation Bio (NUVB) in Q2 2026, closing a stake of 47,827 shares — an estimated $205K sold.

Caxton Associates (UK) first reported a position in NUVB in Q3 2025 and held it in 3 quarters. The position peaked at $5.24M in Q4 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Caxton Associates (UK) reported no remaining Nuvation Bio position as of Q2 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 47,827 Nuvation Bio shares in Q2 2026, an estimated $205K.
  • Caxton Associates (UK) first reported a position in Nuvation Bio in Q3 2025 and held it in 3 quarters.
  • Caxton Associates (UK)'s Nuvation Bio position peaked at $5.24M in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.